Sector Expert: Caroline Corner

Cantor Fitzgerald

Image: Caroline Corner

Dr. Caroline V. Corner, Ph.D., has been a managing director and senior analyst at Cantor Fitzgerald & Co., Research Division, since July 2014. Dr. Corner focuses on equity research of medical technology, ophthalmology and cell therapy companies. Prior to Cantor Fitzgerald, she worked in investor relations at Solazyme Inc. Previously, Dr. Corner served as a managing director and senior research analyst at MLV & Co. LLC. Dr. Corner served as a senior research analyst of regenerative medicine and convergent technologies at Pacific Growth Equities LLC, and worked at Montgomery & Co. LLC, where she served as a senior research analyst covering medical technology companies. She got her start on Wall Street at Wells Fargo Securities LLC as an associate analyst covering medical devices. Prior to working on Wall Street, she held engineering and product development positions at Baxter Transfusion Therapies and Eli Lilly and Co., working in the protein engineering group. Dr. Corner received her Ph.D. in biological and environmental engineering from Cornell University and her bachelor's degree in biological systems engineering at Virginia Tech.



Recent Interviews

Cantor Fitzgerald's Caroline Corner: Cutting-Edge Devices and Diagnostics Deliver Drugs and Profits (7/29/15)
bloodspin.580

Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis. Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors. In this interview with The Life Sciences Report, Corner brings important names to investors' attention.

How to Profit from Hidden Medical Device Gems: Caroline Corner (6/28/12)

Innovation, efficacy and convenience are keys to success in medical devices and diagnostics. Put those elements together with underfollowed names and you have uncovered buried investment treasures. Medical technology research analyst Caroline Corner has assembled a short list of hidden jewels destined for incremental acceptance and then rapid uptake by physicians, clinics and hospitals. In this exclusive interview with The Life Sciences Report, Corner talks about her favorite small-cap companies, none of which are household names.

Recent Quotes

"STEM faces large opportunities in the spine and eye markets."

— Caroline Corner, Cantor Fitzgerald (8/6/15)
more >

"AEMD has approved products that remove viruses, and is now also targeting breast cancer."

The Life Sciences Report Interview with Caroline Corner (7/29/15)
more >

"STEM's spinal program has a good chance of success."

The Life Sciences Report Interview with Caroline Corner (7/29/15)
more >

"STEM is moving forward with the Radiant Phase 2 trial."

— Caroline Corner, Cantor Fitzgerald (6/29/15)
more >

"STEM faces large opportunities in two markets."

— Caroline Corner, Cantor Fitzgerald (6/22/15)
more >



Due to permission requirements, not all quotes are shown.